Home › NDC Lookup › RxCUI directory › RxCUI 2683740

Clobetasol propionate 0.5 MG/ML Ophthalmic Suspension — RxCUI 2683740

RxNorm drug concept · Semantic clinical drug
RxCUI 2683740 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2683740
Official nameClobetasol propionate 0.5 MG/ML Ophthalmic Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asclobetasol propionate 0.05 % Ophthalmic Suspension
FDA products mapped2
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Clobetasol Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Clobetasol propionate shampoo is for moderate to severe scalp psoriasis in adults 18 and older. It is not for use on your face, groin or underarms.
  • Apply a thin film to dry, affected scalp areas once a day. Leave it on for 15 minutes, then lather and rinse well. Wash your hands afterward and keep it away from your eyes and lip...
  • No more than 4 consecutive weeks, and stop sooner if your psoriasis is controlled. If you are not better in 4 weeks, check in with your doctor.
  • Burning, stinging, itching, dryness and acne-like bumps are the most common. Call your doctor if irritation is severe, you see signs of infection, or you notice eye pain or blurred...
📖 Read our full Clobetasol Topical guide →

🕸️ Concept Web — How Clobetasol propionate 0.5 MG/ML Ophthalmic Suspe... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Clobetasol propionate 0.5 MG/ML Ophthalmic Suspension RxCUI 2683740

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Clobetasol 2590
    • Clobetasol propionate 21245
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Byqlovi 2733658
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Clobetasol Ophthalmic Suspension 2683737
    • Clobetasol propionate Ophthalmic Suspension 2683739
    • Clobetasol Ophthalmic Product 2683736
    • Clobetasol propionate Ophthalmic Product 2683738
    • Clobetasol Ophthalmic Suspension [Byqlovi] 2733661
    • Clobetasol propionate Ophthalmic Suspension [Byqlovi] 2733662
    • Byqlovi Ophthalmic Product 2733660
    • Ophthalmic Suspension 316964
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Clobetasol propionate 0.5 MG/ML SCDC · 861352
  • Clobetasol Ophthalmic Suspension SCDF · 2683737
  • Clobetasol propionate Ophthalmic Suspension SCDFP · 2683739
  • Clobetasol Ophthalmic Product SCDG · 2683736
  • Clobetasol propionate Ophthalmic Product SCDGP · 2683738

Brand-Name Concepts

  • Clobetasol propionate 0.5 MG/ML Ophthalmic Suspension [Byqlovi] SBD · 2733663
  • Clobetasol propionate 0.5 MG/ML [Byqlovi] SBDC · 2733659
  • Clobetasol Ophthalmic Suspension [Byqlovi] SBDF · 2733661
  • Clobetasol propionate Ophthalmic Suspension [Byqlovi] SBDFP · 2733662
  • Byqlovi Ophthalmic Product SBDG · 2733660
  • Byqlovi BN · 2733658

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 2683740 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
81046-0319-01 1 BOTTLE, DROPPER in 1 CARTON (81046-0319-1) / 3.5 mL in 1... CLOBETASOL PROPIONATE Eyenovia, Inc. 2024-03-25
82667-0021-00 1 BOTTLE, PLASTIC in 1 CARTON (82667-021-00) / 3.5 mL in 1... BYQLOVI Harrow Eye, LLC 2026-01-25
82667-0021-05 1 BOTTLE, PLASTIC in 1 CARTON (82667-021-05) / 3.5 mL in 1... BYQLOVI Harrow Eye, LLC 2026-01-25
Observed labelers: Harrow Eye, LLC (2) · Eyenovia, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.